 Erik Schadde
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 36 | 2021 | 63 | 12.610 |
Why?
| | Portal Vein | 28 | 2021 | 47 | 10.010 |
Why?
| | Liver Neoplasms | 27 | 2021 | 128 | 9.520 |
Why?
| | Liver | 19 | 2021 | 216 | 6.770 |
Why?
| | Liver Regeneration | 16 | 2020 | 27 | 5.850 |
Why?
| | Colorectal Neoplasms | 12 | 2020 | 121 | 3.890 |
Why?
| | Ligation | 21 | 2020 | 37 | 2.810 |
Why?
| | Embolization, Therapeutic | 6 | 2021 | 82 | 2.650 |
Why?
| | Hepatic Stellate Cells | 2 | 2020 | 10 | 1.590 |
Why?
| | Liver Diseases | 2 | 2018 | 40 | 1.390 |
Why?
| | Cause of Death | 3 | 2017 | 74 | 1.300 |
Why?
| | Registries | 9 | 2019 | 203 | 1.240 |
Why?
| | Laparoscopy | 5 | 2019 | 188 | 1.190 |
Why?
| | Liver Failure | 4 | 2019 | 13 | 1.160 |
Why?
| | Postoperative Complications | 11 | 2019 | 1084 | 1.140 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2021 | 46 | 1.090 |
Why?
| | Hypertrophy | 4 | 2017 | 20 | 0.930 |
Why?
| | Humans | 49 | 2021 | 30741 | 0.920 |
Why?
| | Organ Size | 9 | 2019 | 122 | 0.920 |
Why?
| | Sarcopenia | 1 | 2021 | 33 | 0.890 |
Why?
| | Treatment Outcome | 19 | 2021 | 3850 | 0.870 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 75 | 0.820 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 70 | 0.810 |
Why?
| | Male | 36 | 2021 | 17552 | 0.780 |
Why?
| | Kidney Transplantation | 5 | 2021 | 144 | 0.780 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 12 | 0.770 |
Why?
| | Hepatomegaly | 1 | 2018 | 6 | 0.770 |
Why?
| | Reperfusion Injury | 1 | 2018 | 9 | 0.760 |
Why?
| | Neuroendocrine Tumors | 5 | 2019 | 45 | 0.760 |
Why?
| | Publication Bias | 1 | 2018 | 8 | 0.750 |
Why?
| | Bibliometrics | 1 | 2018 | 20 | 0.730 |
Why?
| | Antioxidants | 1 | 2018 | 70 | 0.720 |
Why?
| | Reactive Oxygen Species | 1 | 2018 | 127 | 0.720 |
Why?
| | Oxidative Stress | 1 | 2018 | 136 | 0.710 |
Why?
| | Retrospective Studies | 15 | 2021 | 3456 | 0.700 |
Why?
| | Neovascularization, Physiologic | 1 | 2017 | 30 | 0.700 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 389 | 0.690 |
Why?
| | Middle Aged | 26 | 2019 | 11256 | 0.670 |
Why?
| | Female | 31 | 2021 | 18107 | 0.640 |
Why?
| | Therapies, Investigational | 1 | 2016 | 4 | 0.640 |
Why?
| | Aged | 20 | 2019 | 10156 | 0.580 |
Why?
| | Graft Rejection | 4 | 2008 | 85 | 0.550 |
Why?
| | Catheter Ablation | 1 | 2015 | 78 | 0.550 |
Why?
| | Liver Transplantation | 3 | 2015 | 110 | 0.520 |
Why?
| | Animals | 8 | 2021 | 5221 | 0.510 |
Why?
| | Blood Loss, Surgical | 3 | 2019 | 71 | 0.500 |
Why?
| | Prognosis | 8 | 2020 | 1045 | 0.470 |
Why?
| | Risk Factors | 10 | 2019 | 2611 | 0.470 |
Why?
| | Time Factors | 9 | 2019 | 1911 | 0.460 |
Why?
| | Feasibility Studies | 4 | 2016 | 283 | 0.450 |
Why?
| | Hepatic Veins | 3 | 2020 | 9 | 0.450 |
Why?
| | Length of Stay | 4 | 2019 | 371 | 0.430 |
Why?
| | Operative Time | 4 | 2019 | 94 | 0.430 |
Why?
| | Survival Rate | 6 | 2018 | 478 | 0.420 |
Why?
| | Models, Animal | 3 | 2020 | 150 | 0.400 |
Why?
| | Follow-Up Studies | 7 | 2018 | 2046 | 0.400 |
Why?
| | Random Allocation | 3 | 2018 | 162 | 0.400 |
Why?
| | Isoantibodies | 2 | 2006 | 11 | 0.390 |
Why?
| | Neoplasm Staging | 5 | 2018 | 516 | 0.390 |
Why?
| | Intestinal Neoplasms | 2 | 2018 | 13 | 0.380 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 174 | 0.370 |
Why?
| | Antibodies, Neoplasm | 1 | 2008 | 18 | 0.370 |
Why?
| | Stomach Neoplasms | 2 | 2018 | 40 | 0.360 |
Why?
| | Swine | 2 | 2018 | 113 | 0.360 |
Why?
| | Death | 1 | 2008 | 45 | 0.360 |
Why?
| | Tissue Donors | 1 | 2008 | 74 | 0.340 |
Why?
| | Rats, Wistar | 2 | 2017 | 69 | 0.340 |
Why?
| | Vascular Surgical Procedures | 2 | 2019 | 55 | 0.340 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 167 | 0.330 |
Why?
| | Patient Selection | 4 | 2018 | 259 | 0.330 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 311 | 0.320 |
Why?
| | Antibody Formation | 1 | 2006 | 32 | 0.320 |
Why?
| | Plasmapheresis | 1 | 2006 | 17 | 0.310 |
Why?
| | HLA Antigens | 1 | 2006 | 21 | 0.310 |
Why?
| | Adult | 15 | 2019 | 9760 | 0.310 |
Why?
| | Rats | 2 | 2020 | 954 | 0.310 |
Why?
| | Risk Assessment | 5 | 2019 | 804 | 0.290 |
Why?
| | Philosophy, Medical | 1 | 2004 | 3 | 0.290 |
Why?
| | Spirituality | 1 | 2004 | 58 | 0.270 |
Why?
| | Tissue and Organ Procurement | 3 | 2012 | 36 | 0.250 |
Why?
| | Multivariate Analysis | 4 | 2019 | 391 | 0.240 |
Why?
| | Cell Proliferation | 2 | 2020 | 238 | 0.230 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 28 | 0.230 |
Why?
| | Databases, Factual | 3 | 2019 | 372 | 0.230 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 135 | 0.220 |
Why?
| | Severity of Illness Index | 2 | 2019 | 1233 | 0.210 |
Why?
| | Biliary Tract Neoplasms | 1 | 2020 | 11 | 0.210 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 321 | 0.210 |
Why?
| | Adrenalectomy | 1 | 2019 | 6 | 0.210 |
Why?
| | Brazil | 2 | 2016 | 32 | 0.200 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2019 | 13 | 0.200 |
Why?
| | Adrenocortical Carcinoma | 1 | 2019 | 12 | 0.200 |
Why?
| | Disease Susceptibility | 1 | 2020 | 84 | 0.200 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 114 | 0.200 |
Why?
| | Ultrasonography | 2 | 2018 | 204 | 0.200 |
Why?
| | Conversion to Open Surgery | 1 | 2019 | 4 | 0.200 |
Why?
| | Abdominal Neoplasms | 1 | 2019 | 13 | 0.190 |
Why?
| | Liver Function Tests | 4 | 2017 | 32 | 0.190 |
Why?
| | Gallium Radioisotopes | 1 | 2018 | 3 | 0.190 |
Why?
| | Preoperative Period | 1 | 2019 | 73 | 0.190 |
Why?
| | bcl-2-Associated X Protein | 1 | 2018 | 14 | 0.190 |
Why?
| | Culture Media, Conditioned | 1 | 2018 | 33 | 0.190 |
Why?
| | Paracrine Communication | 1 | 2018 | 8 | 0.190 |
Why?
| | Cytoprotection | 1 | 2018 | 12 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 33 | 0.190 |
Why?
| | Hepatocytes | 1 | 2018 | 13 | 0.190 |
Why?
| | Organometallic Compounds | 1 | 2018 | 25 | 0.190 |
Why?
| | Anesthesia | 1 | 2018 | 27 | 0.190 |
Why?
| | Hospital Mortality | 3 | 2015 | 187 | 0.190 |
Why?
| | Digestive System Surgical Procedures | 1 | 2018 | 27 | 0.190 |
Why?
| | Venous Thrombosis | 1 | 2019 | 48 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 56 | 0.180 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 54 | 0.180 |
Why?
| | Gastric Bypass | 1 | 2018 | 55 | 0.180 |
Why?
| | Portal Pressure | 1 | 2017 | 5 | 0.180 |
Why?
| | Liver Circulation | 1 | 2017 | 6 | 0.180 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 296 | 0.170 |
Why?
| | Logistic Models | 3 | 2016 | 479 | 0.170 |
Why?
| | Survival Analysis | 2 | 2017 | 398 | 0.170 |
Why?
| | Models, Biological | 1 | 2020 | 428 | 0.170 |
Why?
| | Hyperplasia | 1 | 2017 | 28 | 0.170 |
Why?
| | Fatty Liver | 1 | 2017 | 40 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 876 | 0.170 |
Why?
| | Apoptosis | 1 | 2018 | 291 | 0.170 |
Why?
| | Melanoma | 1 | 2017 | 74 | 0.160 |
Why?
| | Cell Hypoxia | 1 | 2016 | 17 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 361 | 0.160 |
Why?
| | Cholangiocarcinoma | 1 | 2016 | 8 | 0.160 |
Why?
| | Bile Duct Neoplasms | 1 | 2016 | 10 | 0.160 |
Why?
| | Reproducibility of Results | 1 | 2019 | 875 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 198 | 0.150 |
Why?
| | Primary Graft Dysfunction | 1 | 2015 | 3 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2017 | 235 | 0.150 |
Why?
| | Methyl Ethers | 1 | 2015 | 8 | 0.150 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 13 | 0.150 |
Why?
| | Anesthetics, Inhalation | 1 | 2015 | 12 | 0.150 |
Why?
| | Propofol | 1 | 2015 | 16 | 0.150 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 37 | 0.150 |
Why?
| | Obesity | 1 | 2018 | 322 | 0.150 |
Why?
| | Signal Transduction | 1 | 2018 | 582 | 0.150 |
Why?
| | Cohort Studies | 3 | 2017 | 1959 | 0.150 |
Why?
| | Surgeons | 1 | 2016 | 76 | 0.140 |
Why?
| | Safety | 1 | 2014 | 57 | 0.140 |
Why?
| | Disease Models, Animal | 1 | 2018 | 831 | 0.140 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 109 | 0.140 |
Why?
| | Viscera | 1 | 2013 | 2 | 0.130 |
Why?
| | Vascular Patency | 1 | 2013 | 26 | 0.130 |
Why?
| | Renal Artery | 1 | 2013 | 10 | 0.130 |
Why?
| | Aneurysm | 1 | 2013 | 15 | 0.130 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 27 | 0.130 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2013 | 45 | 0.130 |
Why?
| | Pancreas Transplantation | 1 | 2012 | 9 | 0.130 |
Why?
| | Blood Transfusion | 1 | 2012 | 68 | 0.120 |
Why?
| | Endovascular Procedures | 1 | 2013 | 78 | 0.120 |
Why?
| | Bilirubin | 2 | 2016 | 14 | 0.120 |
Why?
| | Resource Allocation | 1 | 2011 | 5 | 0.120 |
Why?
| | Health Care Rationing | 1 | 2011 | 7 | 0.120 |
Why?
| | Linear Models | 1 | 2012 | 277 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2011 | 17 | 0.120 |
Why?
| | Stents | 1 | 2013 | 158 | 0.120 |
Why?
| | Histocompatibility Testing | 1 | 2009 | 6 | 0.100 |
Why?
| | Liver Cirrhosis | 2 | 2012 | 61 | 0.100 |
Why?
| | HLA-C Antigens | 1 | 2009 | 9 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2008 | 8 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 1 | 2008 | 18 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.090 |
Why?
| | Disease-Free Survival | 2 | 2019 | 247 | 0.090 |
Why?
| | Blood Vessels | 1 | 2007 | 19 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2008 | 56 | 0.090 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 75 | 0.090 |
Why?
| | Graft Survival | 1 | 2008 | 111 | 0.090 |
Why?
| | Switzerland | 2 | 2018 | 8 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2007 | 52 | 0.090 |
Why?
| | Kidney Failure, Chronic | 1 | 2009 | 175 | 0.090 |
Why?
| | Cytomegalovirus Infections | 1 | 2008 | 84 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 137 | 0.080 |
Why?
| | Incidence | 2 | 2021 | 827 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 180 | 0.080 |
Why?
| | HLA-DP Antigens | 1 | 2006 | 1 | 0.080 |
Why?
| | Complement C4b | 1 | 2006 | 3 | 0.080 |
Why?
| | Body Mass Index | 2 | 2018 | 438 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2006 | 121 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2017 | 5172 | 0.070 |
Why?
| | Religion and Medicine | 1 | 2004 | 24 | 0.070 |
Why?
| | Hospitals, University | 2 | 2018 | 45 | 0.070 |
Why?
| | Naphthoquinones | 1 | 2021 | 6 | 0.060 |
Why?
| | Benzofurans | 1 | 2021 | 8 | 0.060 |
Why?
| | Aniline Compounds | 1 | 2021 | 40 | 0.060 |
Why?
| | Transplant Recipients | 1 | 2021 | 18 | 0.060 |
Why?
| | Pancreas | 1 | 2021 | 36 | 0.060 |
Why?
| | Cold Ischemia | 2 | 2011 | 3 | 0.060 |
Why?
| | Sulfonamides | 1 | 2021 | 66 | 0.060 |
Why?
| | Mice | 2 | 2021 | 1843 | 0.050 |
Why?
| | Mitotane | 1 | 2019 | 3 | 0.050 |
Why?
| | Kidney | 1 | 2021 | 209 | 0.050 |
Why?
| | Argentina | 1 | 2019 | 1 | 0.050 |
Why?
| | Preoperative Care | 1 | 2020 | 149 | 0.050 |
Why?
| | Blood Coagulation Disorders | 1 | 2019 | 16 | 0.050 |
Why?
| | Digestive System Neoplasms | 1 | 2018 | 6 | 0.050 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2018 | 17 | 0.050 |
Why?
| | Serum Albumin | 1 | 2019 | 28 | 0.050 |
Why?
| | Thymus Neoplasms | 1 | 2018 | 14 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2018 | 7 | 0.050 |
Why?
| | Europe | 1 | 2019 | 86 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 473 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 148 | 0.050 |
Why?
| | United States | 2 | 2018 | 2467 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2017 | 58 | 0.040 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2017 | 27 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2017 | 45 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 293 | 0.040 |
Why?
| | Anticoagulants | 1 | 2019 | 147 | 0.040 |
Why?
| | Edema | 1 | 2017 | 39 | 0.040 |
Why?
| | Treatment Failure | 1 | 2017 | 188 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2017 | 122 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 421 | 0.040 |
Why?
| | Italy | 1 | 2016 | 17 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2017 | 82 | 0.040 |
Why?
| | Medical Audit | 1 | 2016 | 8 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 10 | 0.040 |
Why?
| | Rabbits | 1 | 2017 | 327 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 230 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2016 | 76 | 0.040 |
Why?
| | Belgium | 1 | 2015 | 3 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2017 | 501 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2015 | 20 | 0.040 |
Why?
| | Age Factors | 1 | 2018 | 941 | 0.040 |
Why?
| | Sarcoma | 1 | 2017 | 124 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2016 | 79 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 385 | 0.040 |
Why?
| | Odds Ratio | 1 | 2015 | 328 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 631 | 0.030 |
Why?
| | Graft Occlusion, Vascular | 1 | 2013 | 24 | 0.030 |
Why?
| | Prospective Studies | 1 | 2018 | 1891 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2017 | 440 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 694 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2018 | 753 | 0.030 |
Why?
| | Waiting Lists | 1 | 2011 | 19 | 0.030 |
Why?
| | Health Status Indicators | 1 | 2012 | 82 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2011 | 78 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 1244 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2009 | 16 | 0.030 |
Why?
| | Immunization | 1 | 2009 | 49 | 0.030 |
Why?
| | Algorithms | 1 | 2012 | 421 | 0.020 |
Why?
| | Receptors, CXCR3 | 1 | 2007 | 2 | 0.020 |
Why?
| | Histocompatibility | 1 | 2007 | 5 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 29 | 0.020 |
Why?
| | Child | 1 | 2012 | 1547 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 289 | 0.020 |
Why?
| | Wisconsin | 1 | 2006 | 6 | 0.020 |
Why?
| | Kidney Tubules | 1 | 2006 | 13 | 0.020 |
Why?
| | Atrophy | 1 | 2006 | 107 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2006 | 85 | 0.020 |
Why?
|
|
Schadde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|